# FDA Post-Marketing Surveillance | Evidence-Based Decision Making in Healthcare â€“ Part 13
*Course: Evidence-Based Decision Making in Healthcare*  
*Instructor: Dr. Jay K. Varma â€“ Physician, Epidemiologist, and Public Health Expert*  
[https://drjayvarma.com](https://drjayvarma.com)

## Overview
What happens after a drug or medical device is approved for use? In this lecture, Dr. Jay Varma explains the critical role of **FDA post-marketing surveillance** in safeguarding public health. From safety signal detection to regulatory action, the presentation highlights how surveillance systems protect patients and improve product safety over time.

Students will learn how the FDA collects and analyzes safety data, the challenges posed by underreporting, and how big data, provider engagement, and patient reporting can strengthen pharmacovigilance.

## Key Topics Covered
1. FDA post-marketing surveillance processes and goals  
2. MedWatch and adverse event reporting systems  
3. Phase 4 trials and regulatory follow-up  
4. Case studies of post-marketing safety actions  
5. Strategies to improve detection and response  

## Resources
- ðŸ“‘ [Slides (PDF)](lecture-13-fda-post-marketing-surveillance.pdf)  
- ðŸ“‚ [Slides (PowerPoint)](lecture-13-fda-post-marketing-surveillance.pptx)

## About the Course
This presentation is **Part 13 of a 15-part course** titled *Evidence-Based Decision Making in Healthcare*, developed and taught by Dr. Jay K. Varma â€” physician, epidemiologist, and expert in global public health.

The course teaches students, practitioners, and policymakers how to apply scientific evidence, structured frameworks, and ethical reasoning to make better decisions in healthcare and public health.

ðŸ”— **Explore the full series and related resources:** [https://drjayvarma.com](https://drjayvarma.com)

